Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

Real-world evidence suggests a trend toward inferior survival of patients receiving CD19 chimeric antigen receptor (CAR) T-cell therapy in Europe (EU) and with tisagenlecleucel. The underlying logistic, patient- and disease-related reasons for these discrepancies remain poorly understood. In this mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Bücklein, Veit, Perez, Ariel, Rejeski, Kai, Iacoboni, Gloria, Jurinovic, Vindi, Holtick, Udo, Penack, Olaf, Kharboutli, Soraya, Blumenberg, Viktoria, Ackermann, Josephine, Frölich, Lisa, Johnson, Grace, Patel, Kedar, Arciola, Brian, Mhaskar, Rahul, Wood, Anthony, Schmidt, Christian, Albanyan, Omar, Gödel, Philipp, Hoster, Eva, Bullinger, Lars, Mackensen, Andreas, Locke, Frederick, von Bergwelt, Michael, Barba, Pere, Subklewe, Marion, Jain, Michael D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337711/
https://www.ncbi.nlm.nih.gov/pubmed/37449196
http://dx.doi.org/10.1097/HS9.0000000000000907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337711/
https://www.ncbi.nlm.nih.gov/pubmed/37449196
http://dx.doi.org/10.1097/HS9.0000000000000907

Ejemplares similares